Answers are grounded in this paper and cite their sources.
Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. Methods: A total of 20 patients, 8 male (33-56-years, average 41.4±7.8) and 12 female (19-61-years, average 38.5±11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1200 mg/day) in combination with NSAIDs for up to 90 days . They were revaluated at 30, 60 and 90 days after treatment. Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P=0.01189; female P=<0.01) and they lasted until the end of the study (male P=0.0066; female P=0.01473). Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.
No takes yet. Share an insight, caveat, or question.
Chirchiglia et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: